NI201400093A - Procesos para la preparación de (s) -1- ( 3 - etoxi - 4 - metoxifenil) - 2 - metanosulfoniletilamino - Google Patents

Procesos para la preparación de (s) -1- ( 3 - etoxi - 4 - metoxifenil) - 2 - metanosulfoniletilamino

Info

Publication number
NI201400093A
NI201400093A NI201400093A NI201400093A NI201400093A NI 201400093 A NI201400093 A NI 201400093A NI 201400093 A NI201400093 A NI 201400093A NI 201400093 A NI201400093 A NI 201400093A NI 201400093 A NI201400093 A NI 201400093A
Authority
NI
Nicaragua
Prior art keywords
processes
preparation
metanosulfoniletilamino
metoxifenil
etoxy
Prior art date
Application number
NI201400093A
Other languages
English (en)
Inventor
Venkateswaralu Jasti
Rajendiran Chinnapillai
Ravikumar Reddy Nallamaddi
Joseph Connolly Terrence
L Ruchelman Alexander
Eckert Jeffrey
Joseph Frank Anthony
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47755073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201400093(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of NI201400093A publication Critical patent/NI201400093A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/06—Sulfinamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan en la presente nuevos procesos para la preparación de intermediarios de aminosulfona para la síntesis de 2 - [ 1 - ( 3 - etoxi - 4 - metoxifenil ) - 2 - metilsulfoniletil ] - 4 - acetilaminoisoindolina - 1, 3 - diona, que es útil para prevenir o tratar enfermedades o afecciones relacionadas con un nivel anormalmente alto o actividad de TNF-alfa. También se proporcionan procesos para la producción comercial de (S) - 1 - ( 3 - etoxi - 4 - metoxifenil ) - 2 - metanosulfoniletilamino.
NI201400093A 2012-02-21 2014-08-20 Procesos para la preparación de (s) -1- ( 3 - etoxi - 4 - metoxifenil) - 2 - metanosulfoniletilamino NI201400093A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261601226P 2012-02-21 2012-02-21

Publications (1)

Publication Number Publication Date
NI201400093A true NI201400093A (es) 2016-11-30

Family

ID=47755073

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201400093A NI201400093A (es) 2012-02-21 2014-08-20 Procesos para la preparación de (s) -1- ( 3 - etoxi - 4 - metoxifenil) - 2 - metanosulfoniletilamino

Country Status (36)

Country Link
US (3) US9187417B2 (es)
EP (4) EP3312156B1 (es)
JP (1) JP2015509496A (es)
KR (1) KR101993248B1 (es)
CN (3) CN104245668B (es)
AR (2) AR090100A1 (es)
AU (1) AU2013203283B2 (es)
BR (3) BR122021020046B1 (es)
CA (1) CA2864517A1 (es)
CO (1) CO7061071A2 (es)
CR (1) CR20140395A (es)
CY (2) CY1121833T1 (es)
DK (2) DK3378850T3 (es)
ES (4) ES2773686T3 (es)
HK (1) HK1205501A1 (es)
HR (2) HRP20191249T1 (es)
HU (2) HUE044192T2 (es)
IL (3) IL234135A (es)
IN (1) IN2014DN06740A (es)
LT (2) LT3378850T (es)
MX (2) MX344190B (es)
MY (1) MY168296A (es)
NI (1) NI201400093A (es)
NZ (1) NZ628028A (es)
PH (1) PH12014501865B1 (es)
PL (2) PL3378850T3 (es)
PT (2) PT3312156T (es)
RS (2) RS59071B1 (es)
RU (1) RU2632875C2 (es)
SG (1) SG11201405035XA (es)
SI (2) SI3378850T1 (es)
TR (1) TR201910430T4 (es)
TW (1) TW201336815A (es)
UA (1) UA116773C2 (es)
WO (1) WO2013126360A2 (es)
ZA (1) ZA201405892B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090100A1 (es) * 2012-02-21 2014-10-22 Celgene Corp Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
US9126906B2 (en) * 2012-02-21 2015-09-08 Celgene Corporation Asymmetric synthetic processes for the preparation of aminosulfone compounds
EP3539539A1 (en) 2013-06-17 2019-09-18 Celgene Corporation Tablet formulations of (+)-2-[1 -(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
IN2014MU01283A (es) 2014-04-04 2015-10-09 Cadila Healthcare Ltd
WO2015173792A1 (en) 2014-05-11 2015-11-19 Mapi Pharma Ltd. Amorphous form of apremilast
EP2949645A1 (en) 2014-05-28 2015-12-02 LEK Pharmaceuticals d.d. Processes for the preparation of ß-aminosulfone compounds
CN105622380B (zh) * 2014-10-29 2020-06-30 南京安源生物医药科技有限公司 一种阿普斯特的制备方法及其中间体
CN104447445B (zh) * 2014-12-05 2016-07-06 新发药业有限公司 一种合成阿普斯特中间体的制备方法
CN104744323B (zh) * 2015-03-11 2016-08-31 中山奕安泰医药科技有限公司 一种阿普斯特手性胺中间体的合成工艺
CN104761474B (zh) * 2015-03-11 2016-11-30 中山奕安泰医药科技有限公司 一种阿普斯特手性胺中间体的合成方法
CN104803897A (zh) * 2015-04-23 2015-07-29 中山奕安泰医药科技有限公司 一种阿普斯特中间体的合成工艺
WO2016174685A1 (en) 2015-04-27 2016-11-03 Mylan Laboratories Limited Process for the enantiomeric resolution of apremilast intermediates
WO2016199031A1 (en) * 2015-06-09 2016-12-15 Dr. Reddy’S Laboratories Limited Process for preparation of apremilast and its intermediates
EP3106457A1 (en) 2015-06-15 2016-12-21 LEK Pharmaceuticals d.d. A novel synthetic pathway towards apremilast
EP3144393A1 (en) 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
WO2017059040A1 (en) 2015-09-29 2017-04-06 Pliva Hrvatska D.O.O. Processes for the preparation of apremilast and intermediates thereof
WO2017085568A1 (en) * 2015-11-19 2017-05-26 Alembic Pharmaceuticals Limited An improved process and novel polymorphic form of apremilast
CN105461602B (zh) * 2015-11-27 2018-01-02 东华大学 手性S或R‑3‑乙氧基‑4‑甲氧基‑α‑[(甲磺酰基)甲基]苯甲醇的制备方法
CN105330586B (zh) * 2015-11-27 2017-12-22 东华大学 一种阿普斯特的制备方法
WO2017094031A2 (en) * 2015-12-04 2017-06-08 Sun Pharmaceutical Industries Limited Novel process for preparation of apremilast
CN106866475B (zh) * 2015-12-11 2018-03-30 北大方正集团有限公司 一种阿普斯特中间体及其制备方法
US10774041B2 (en) 2016-04-15 2020-09-15 Davuluri Ramamohan Rao Process for the preparation of apremilast
US10196355B2 (en) 2016-06-20 2019-02-05 Johnson Matthey Public Limited Company Forms of apremilast
CN106543050B (zh) * 2016-09-28 2018-04-10 中南大学湘雅医院 一种阿普斯特中间体的合成工艺
WO2018061034A1 (en) * 2016-09-30 2018-04-05 Sun Pharmaceutical Industries Limited Novel process for the preparation of 1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethanamine
US11000888B2 (en) 2016-11-10 2021-05-11 Sms Group Gmbh Method for producing a metal strip in a cast-rolling installation
CN107445875A (zh) * 2017-03-22 2017-12-08 陕西科技大学 一种用于制备阿普斯特的高纯度中间体的手性拆分方法
EP3606907B1 (en) 2017-04-04 2021-01-20 Quimica Sintetica, S.A. Racemic beta-aminosulfone compounds
SI3606908T1 (sl) 2017-04-04 2020-10-30 Quimica Sintetica, S.A. Delitev racemičnih beta-aminosulfonskih spojin
CN107941945B (zh) * 2017-11-23 2020-12-22 中山奕安泰医药科技有限公司 一种3-乙氧基-4-甲氧基苯甲腈的检测方法
CN108008035B (zh) * 2017-11-23 2020-07-07 中山奕安泰医药科技有限公司 3-乙氧基-4-甲氧基苯甲醛纯度的检测方法
CN107976501B (zh) * 2017-11-23 2020-08-25 中山奕安泰医药科技有限公司 一种1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法
CN107966509B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种(s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法
CN107827722B (zh) * 2017-11-23 2021-02-19 中山奕安泰医药科技有限公司 一种3-乙氧基-4-甲氧基苯甲醛的合成方法
CN108084066A (zh) * 2017-12-12 2018-05-29 中山大学 一种阿普斯特及对映异构体的合成方法
JP6673614B1 (ja) * 2018-10-16 2020-03-25 東芝エレベータ株式会社 防音装置
CN113896674B (zh) * 2021-09-01 2023-10-27 深圳华中科技大学研究院 一种阿普斯特的合成方法
CN116332954A (zh) 2021-12-21 2023-06-27 赣州和美药业股份有限公司 噻吩衍生物的制备
CN115850129B (zh) * 2023-02-28 2023-05-16 凯莱英生命科学技术(天津)有限公司 （s）-1-(3-乙氧基-4-甲氧基苯基)-2-（甲磺酰基）乙胺的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1261455A (en) * 1969-03-06 1972-01-26 Burroughs Wellcome Co Improvements in or relating to substituted acrylonitriles
US3878252A (en) * 1970-09-24 1975-04-15 Burroughs Wellcome Co Ring substituted beta-hydroxy-phenyethylmethyl sulphone or sulphoxide
DE2051871A1 (en) * 1969-05-16 1971-11-18 The Wellcome Foundation Ltd., London Beta-amino-alpha-aryloxymethylacrylonitrile - and 2,4-diamino-5-benzylpyrimidine derivs. useful as antibacterial agents
EE9800299A (et) 1996-03-22 1999-06-15 The Du Pont Merck Pharmaceutical Company R-a-propüül-piperonüülamiini ja selle analoogide uudne asümmeetriline sünteesimine
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
ATE449081T1 (de) 2002-12-30 2009-12-15 Celgene Corp Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
US7208526B2 (en) 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
WO2009094528A1 (en) * 2008-01-25 2009-07-30 High Point Pharmaceuticals, Llc TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-α SYNTHESIS AND AS PDE4 INHIBITORS
EP2334639B1 (en) * 2008-09-10 2013-01-23 Celgene Corporation Processes for the preparation of aminosulfone compounds
PT2443089E (pt) * 2009-06-18 2014-06-23 Concert Pharmaceuticals Inc Derivados de isoindolina-1,3-diona deuterados como inibidores de pde4 e tnf-alfa
RU2557236C2 (ru) 2009-10-09 2015-07-20 Селджин Корпорейшн Способ получения соединений 2-(1-фенилэтил)изоиндолин-1-она
US9045417B2 (en) 2011-01-14 2015-06-02 Celgene Corporation Isotopologues of isoindole derivatives
US9126906B2 (en) * 2012-02-21 2015-09-08 Celgene Corporation Asymmetric synthetic processes for the preparation of aminosulfone compounds
AR090100A1 (es) * 2012-02-21 2014-10-22 Celgene Corp Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina

Also Published As

Publication number Publication date
ES2735801T3 (es) 2019-12-20
KR20140126389A (ko) 2014-10-30
EP3312156A1 (en) 2018-04-25
TR201910430T4 (tr) 2019-08-21
MY168296A (en) 2018-10-23
PL3378850T3 (pl) 2020-07-27
CN104245668B (zh) 2017-05-17
LT3312156T (lt) 2019-08-12
MX2014010002A (es) 2014-09-08
PT3312156T (pt) 2019-07-19
RS60036B1 (sr) 2020-04-30
EP3378850B8 (en) 2020-03-04
BR112014020444B1 (pt) 2021-12-07
SG11201405035XA (en) 2014-09-26
ES2971710T3 (es) 2024-06-06
IL252459B (en) 2020-03-31
PT3378850T (pt) 2020-03-06
US9688623B2 (en) 2017-06-27
PH12014501865A1 (en) 2014-11-17
EP3312156B1 (en) 2019-06-05
EP2817288A2 (en) 2014-12-31
EP3378850B1 (en) 2020-01-08
DK3378850T3 (da) 2020-03-16
CY1122799T1 (el) 2021-05-05
RU2632875C2 (ru) 2017-10-11
US20160031808A1 (en) 2016-02-04
AR117963A2 (es) 2021-09-08
CN107033042A (zh) 2017-08-11
HK1205501A1 (en) 2015-12-18
CN104245668A (zh) 2014-12-24
AU2013203283B2 (en) 2015-11-26
WO2013126360A2 (en) 2013-08-29
CN112812044A (zh) 2021-05-18
KR101993248B1 (ko) 2019-06-26
IL234135A (en) 2017-06-29
IN2014DN06740A (es) 2015-05-22
BR122021020040B1 (pt) 2022-05-31
RU2014138037A (ru) 2016-04-10
EP3702347A1 (en) 2020-09-02
UA116773C2 (uk) 2018-05-10
EP3378850A1 (en) 2018-09-26
CN112812044B (zh) 2023-05-30
JP2015509496A (ja) 2015-03-30
BR122021020046B1 (pt) 2022-05-31
CA2864517A1 (en) 2013-08-29
HRP20200245T1 (hr) 2020-05-15
IL273050A (en) 2020-04-30
MX350731B (es) 2017-09-15
CO7061071A2 (es) 2014-09-19
ES2773686T3 (es) 2020-07-14
US20170129852A1 (en) 2017-05-11
CY1121833T1 (el) 2020-10-14
SI3378850T1 (sl) 2020-07-31
HRP20191249T1 (hr) 2019-10-18
DK3312156T3 (da) 2019-07-22
HUE048412T2 (hu) 2020-07-28
MX344190B (es) 2016-12-08
CR20140395A (es) 2014-11-17
RS59071B1 (sr) 2019-09-30
ZA201405892B (en) 2015-11-25
LT3378850T (lt) 2020-04-10
PL3312156T3 (pl) 2019-10-31
SI3312156T1 (sl) 2019-09-30
US20130217918A1 (en) 2013-08-22
AU2013203283A1 (en) 2013-09-05
US9187417B2 (en) 2015-11-17
ES2675168T3 (es) 2018-07-09
US9586897B2 (en) 2017-03-07
PH12014501865B1 (en) 2014-11-17
IL252459A0 (en) 2017-07-31
NZ628028A (en) 2016-03-31
HUE044192T2 (hu) 2019-10-28
BR112014020444A2 (pt) 2020-10-27
EP2817288B1 (en) 2018-05-30
AR090100A1 (es) 2014-10-22
EP3702347B1 (en) 2023-11-08
TW201336815A (zh) 2013-09-16
WO2013126360A3 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
NI201400093A (es) Procesos para la preparación de (s) -1- ( 3 - etoxi - 4 - metoxifenil) - 2 - metanosulfoniletilamino
GT201400034A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
EA201391019A1 (ru) Соединения и способы для модуляции киназ, а также показания к их применению
TN2014000063A1 (en) Kinase inhibitor polymorphs
BR112017013382A2 (pt) método para preparar um composto, composto, e, ácido.
EA201492219A1 (ru) Соединения и композиции для модуляции egfr активности
DOP2017000013A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
BR112016025132A2 (pt) compostos polifluorados agindo como inibidores de tirosina quinase de bruton
ECSP13012993A (es) Inhibidores de nampt y rock
UY34445A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
UY34216A (es) Nuevos compuestos que inhiben la actividad de la Lp-PLA2
DK3473278T3 (da) Fremgangsmåde til enzymatisk behandling af vævsprodukter
GT201300258A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
MX2016002587A (es) Modulacion de la expresion de precalicreina (pkk).
GT201400090A (es) 2-tiopirimidinonas
DOP2016000120A (es) Nuevos inhibidores de dgat2
BR112013016241A2 (pt) composto, e, método para fabricar um composto
UY34612A (es) ?procedimiento para la preparación de derivados de isoxazolina azetidina quirales como agentes antiparasitarios?.
EA201270176A1 (ru) Производные тазаротена
UY34277A (es) Metodo para la eliminación del naftaleno
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
UY33972A (es) Proceso para la producción de carbonato de nikel
TH1401003680A (th) สูตรผสมของ (+)-2-[1-(3-อีธอกซิ-4-เมธอกซิ-ฟีนิล)-2-มีเธนซัลโฟนิล-เอธิล]-4- อะซิติลอะมิโนไอโซอินโดไลน์-1,3-ไดโอน
ES2388965B1 (es) PROCEDIMIENTO PARA LA SINTESIS DE LACTONAS DERIVADAS DEL ACIDO p-HIDROXIFENIL PROPIONICO MEJORADO.